Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M B Martin

Showing results (81-90 of 98) with videos related to

Pageof 10
Sort By:
Cancer Research|April 23, 2009
Poly(ADP-ribose) polymerase-1 inhibitor treatment regresses autochthonous Brca2/p53-mutant mammary tumors in vivo and delays tumor relapse in combination with carboplatinTrevor Hay, James R Matthews, Lucie Pietzka, et al.
Bioorganic & Medicinal Chemistry Letters|June 27, 2008
Novel alkoxybenzamide inhibitors of poly(ADP-ribose) polymeraseKeith A Menear, Claire Adcock, Francisco Cuenca Alonso, et al.
Journal of Medicinal Chemistry|April 13, 2001
Bisphosphonates inhibit the growth of Trypanosoma brucei, Trypanosoma cruzi, Leishmania donovani, Toxoplasma gondii, and Plasmodium falciparum: a potential route to chemotherapyM B Martin, J S Grimley, J C Lewis, et al.
Leukemia|October 24, 2012
Efficacy of the investigational mTOR kinase inhibitor MLN0128/INK128 in models of B-cell acute lymphoblastic leukemiaM R Janes, C Vu, S Mallya, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|April 7, 2018
Pathology findings and clinical outcomes after risk reduction salpingo-oophorectomy in BRCA mutation carriers: a multicenter Spanish studyL Minig, S Cabrera, R Oliver, et al.
Nature|April 15, 2005
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategyHannah Farmer, Nuala McCabe, Christopher J Lord, et al.
Journal of Medicinal Chemistry|March 23, 2011
5-Benzamidoisoquinolin-1-ones and 5-(ω-carboxyalkyl)isoquinolin-1-ones as isoform-selective inhibitors of poly(ADP-ribose) polymerase 2 (PARP-2)Peter T Sunderland, Esther C Y Woon, Archana Dhami, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 19, 2008
Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatinBastiaan Evers, Rinske Drost, Eva Schut, et al.
Cancer Discovery|October 30, 2012
Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumorsJanneke E Jaspers, Ariena Kersbergen, Ute Boon, et al.
Bioorganic & Medicinal Chemistry Letters|September 8, 2009
Identification and optimisation of novel and selective small molecular weight kinase inhibitors of mTORKeith A Menear, Sylvie Gomez, Karine Malagu, et al.
Pageof 10

Showing results (81-90 of 98) with videos related to

Sort By:
Pageof 10
Cancer Research|April 23, 2009
Poly(ADP-ribose) polymerase-1 inhibitor treatment regresses autochthonous Brca2/p53-mutant mammary tumors in vivo and delays tumor relapse in combination with carboplatinTrevor Hay, James R Matthews, Lucie Pietzka, et al.
Bioorganic & Medicinal Chemistry Letters|June 27, 2008
Novel alkoxybenzamide inhibitors of poly(ADP-ribose) polymeraseKeith A Menear, Claire Adcock, Francisco Cuenca Alonso, et al.
Journal of Medicinal Chemistry|April 13, 2001
Bisphosphonates inhibit the growth of Trypanosoma brucei, Trypanosoma cruzi, Leishmania donovani, Toxoplasma gondii, and Plasmodium falciparum: a potential route to chemotherapyM B Martin, J S Grimley, J C Lewis, et al.
Leukemia|October 24, 2012
Efficacy of the investigational mTOR kinase inhibitor MLN0128/INK128 in models of B-cell acute lymphoblastic leukemiaM R Janes, C Vu, S Mallya, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|April 7, 2018
Pathology findings and clinical outcomes after risk reduction salpingo-oophorectomy in BRCA mutation carriers: a multicenter Spanish studyL Minig, S Cabrera, R Oliver, et al.
Nature|April 15, 2005
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategyHannah Farmer, Nuala McCabe, Christopher J Lord, et al.
Journal of Medicinal Chemistry|March 23, 2011
5-Benzamidoisoquinolin-1-ones and 5-(ω-carboxyalkyl)isoquinolin-1-ones as isoform-selective inhibitors of poly(ADP-ribose) polymerase 2 (PARP-2)Peter T Sunderland, Esther C Y Woon, Archana Dhami, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 19, 2008
Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatinBastiaan Evers, Rinske Drost, Eva Schut, et al.
Cancer Discovery|October 30, 2012
Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumorsJanneke E Jaspers, Ariena Kersbergen, Ute Boon, et al.
Bioorganic & Medicinal Chemistry Letters|September 8, 2009
Identification and optimisation of novel and selective small molecular weight kinase inhibitors of mTORKeith A Menear, Sylvie Gomez, Karine Malagu, et al.
Pageof 10